Stockscreener 앱 받기
64.10
1.38%
-0.90
시간 외 거래:
64.10
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Baird lifts Mirum Pharmaceuticals, Inc. (MIRM) price target on Bluejay Therapeutics acquisition - MSN
The week in pharma: action, reaction and insight – week to December 12 - The Pharma Letter
Eventide Asset Management LLC Has $134.22 Million Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by BVF Inc. IL - MarketBeat
Boone Capital Management LLC Has $32.64 Million Stock Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Rx Rundown: Pfizer, Mirum Pharmaceuticals, Novartis and more - Medical Marketing and Media
Mirum Pharmaceuticals stock price target raised to $110 by Raymond James - Investing.com Canada
Baird Lifts Mirum Pharmaceuticals, Inc. (MIRM) Price Target on Bluejay Therapeutics Acquisition - Insider Monkey
Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition - Insider Monkey
What is HC Wainwright's Forecast for MIRM FY2025 Earnings? - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2025 - BioSpace
Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback - Yahoo Finance
Mirum expands into liver diseases with Bluejay Therapeutics acquisition - MSN
Mirum Pharmaceuticals (Nasdaq: MIRM) approves stock option and RSU inducement grants for 8 new hires - Stock Titan
Mirum Pharmaceuticals stock price target raised to $100 by Leerink - Investing.com Canada
Trading Systems Reacting to (MIRM) Volatility - news.stocktradersdaily.com
Baird Maintains Mirum Pharmaceuticals (MIRM) Outperform Recommendation - Nasdaq
Mirum adds to liver disease pipeline with Bluejay takeout: Deals Report - BioCentury
One Peninsula drug maker to buy another for up to $820 million around drug cut by Novartis - The Business Journals
Mirum Pharmaceuticals' Bluejay Acquisition Expands Liver Disease Pipeline, Morgan Stanley Says - marketscreener.com
Mirum Pharmaceuticals stock rises as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Canada
Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald - Yahoo Finance
Mirum to buy Bluejay for up to $820m in rare liver disease push - Yahoo Finance
Morgan Stanley Raises Price Target on Mirum Pharmaceuticals to $95 From $81, Keeps Overweight Rating - marketscreener.com
Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Jump Financial LLC - MarketBeat
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - BioSpace
Five things for pharma marketers to know for Tuesday, December 9, 2025 - Medical Marketing and Media
Baird raises Mirum Pharmaceuticals stock price target to $88 on Bluejay acquisition - Investing.com Canada
Mirum to acquire Bluejay for $620 million, adding HDV treatment By Investing.com - Investing.com Canada
Mirum Pharma to buy Bluejay Therapeutics for up to $820 million - WTVB
Mirum Adds To Rare Liver Disease Portfolio With Bluejay Acquisition - Citeline News & Insights
Mirum Pharmaceuticals stock rises as Morgan Stanley reiterates Overweight rating - Investing.com Canada
Mirum Pharmaceuticals, Inc. (MIRM) Bluejay Therapeutics, Inc.,M&A CallSlideshow (NASDAQ:MIRM) 2025-12-08 - Seeking Alpha
MIRM: Acquisition brings a breakthrough hepatitis delta therapy, expanding rare disease leadership - TradingView
Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay - BioPharma Dive
Mirum Pharmaceuticals, Inc. entered into a definitive agreement to acquire Bluejay Therapeutics, Inc for $820 million. - marketscreener.com
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' - MSN
Latham & Watkins Advises Bluejay Therapeutics in US$620 Million+ Acquisition by Mirum Pharmaceuticals - Latham & Watkins LLP
Mirum Pharma to buy Bluejay Therapeutics for up to $820M - Axios
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Gl - pharmiweb.com
Mirum Pharmaceuticals To Acquire Bluejay Therapeutics In Rare Liver Disease Expansion - Nasdaq
Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug - marketscreener.com
Mirum Pharmaceuticals to Acquire Bluejay Therapeutics - Contract Pharma
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics - marketscreener.com
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million - TradingView — Track All Markets
Mirum to acquire Bluejay for $620 million, adding HDV treatment - Investing.com
Mirum Pharmaceuticals enters into definitive agreement to acquire Bluejay Therapeutics - marketscreener.com
Mirum Pharmaceuticals (NASDAQ: MIRM) to acquire Bluejay Therapeutics, adds HDV drug brelovitug and $200M PIPE - Stock Titan
Mirum Pharmaceuticals (MIRM) up 1.3% since last earnings report: Can it continue? - MSN
Affinity Asset Advisors LLC Cuts Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
MIRM SEC FilingsMirum Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
How geopolitical risks impact Mirum Pharmaceuticals Inc. (08D) stockWeekly Earnings Recap & AI Driven Stock Price Forecasts - Newser
How Mirum Pharmaceuticals Inc. (08D) stock responds to job market shiftsJuly 2025 Trends & Consistent Profit Trade Alerts - Newser
Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) - Yahoo Finance
Is Mirum Pharmaceuticals Inc. (08D) stock worth buying before Fed action2025 Market Sentiment & Daily Market Momentum Tracking - Newser
0.36%
1.05%
자본화:
|
볼륨(24시간):